Clinical trials: Heart Failure With Reduced Ejection Fraction
Heart Failure and Preserved Ejection Fraction, Heart Failure
Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure
The goal of this clinical trial is to evaluate the impact of Finerenone on myocardial remodeling in patients with diabetic kidney disease (DKD) and heart failure with a left ventricular ejection fraction (LVEF) ≥ 40%.
- Conditions
- Heart Failure and Preserved Ejection Fraction, Heart Failure, Heart Failure and Mildly Reduced Ejection Fraction
- Trial name
- FINE-REMODEL (NCT07442448)
- Testing
- Finerenone
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Cathay General Hospital
Heart Failure With Reduced Ejection Fraction, Renal Insufficiency
Telmisartan Versus Enalapril in Heart Failure With Reduced Ejection Fraction Patients With Moderately Impaired Kidney Functions
Heart Failure (HF) poses a major health burden in various populations, with devastating annual rates of morbidity and mortality. It is estimated that 1%-to-2% of the general population suffer from the heart failure syndrome.
- Trial name
- TRIUMF (NCT04736329)
- Testing
- Telmisartan
- Where
- Egypt
- Volunteers
- 107 people
- Sponsor
- Cairo University
Heart Failure
Comparison of Three-dimensional and Two-dimensional Left Ventricle Strain With Speckle-tracking Echocardiography in Heart Failure With Reduced and Mildly Reduced Ejection Fraction
This study will compare two ultrasound techniques, 2D and 3D speckle-tracking echocardiography, for measuring how well the heart muscle contracts in patients with heart failure and reduced pumping function.
- Trial name
- 3V2-STEM-HF (NCT07741305)
- Where
- 5 sites in Italy
- Volunteers
- 419 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Heart Failure With Reduced Ejection Fraction, Heart Failure; With Decompensation
Improving Knowledge in Heart Failure Inpatient With Therapeutic Education
The objective is to evaluate the impact of a pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients.
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure; With Decompensation, Pharmacist-Patient Relations, Medication Adherence
- Trial name
- EDUC-IC (NCT05751772)
- Testing
- Patient therapeutic education
- Where
- Switzerland
- Volunteers
- 38 people
- Sponsor
- University Hospital, Geneva
Heart Failure, Systolic
TRANSFORM Heart Failure with Reduced Ejection Fraction
The goal of the TRANSFORM-HFrEF trial will be to study the current guideline-directed medical therapy (GDMT) landscape for HFrEF and determine effective methods and models of increasing adherence to GDMT and improving Quality of…
- Trial name
- TRANSFORMHFrEF (NCT04872959)
- Testing
- HealthReveal
- Sponsor
- Massachusetts General Hospital
Heart Failure With Reduced Ejection Fraction
HFrEF Polypill in Sri Lanka RCT
The aim of this study is to evaluate, in adults with HFrEF in Sri Lanka, the effects of an HFrEF polypill implementation strategy on the composite rate of cardiovascular disease mortality and recurrent heart failure…
- Trial name
- NCT07569640
- Testing
- Usual Care, HFrEF Polypill
- Where
- 12 sites in Sri Lanka
- Volunteers
- 1,672 people
- Sponsor
- Washington University School of Medicine
Heart Failure, Polygenic Score
UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF
This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent.
- Trial name
- UPBEAT (NCT07054489)
- Testing
- Beta blocker
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- David Lanfear
Heart Failure, Dilated Cardiomyopathy
A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure
AUGMENT-HF II is a study to evaluate the efficacy and safety of the Algisyl device. The purpose of this study is to investigate Algisyl employed as a method of left ventricular augmentation and restoration in patients with…
- Conditions
- Heart Failure, Dilated Cardiomyopathy, Heart Failure With Reduced Ejection Fraction
- Trial name
- AUGMENT-HFII (NCT03082508)
- Testing
- Algisyl, Standard Medical Therapy
- Volunteers
- 240 people
- Sponsor
- LoneStar Heart, Inc.
Acute Heart Failure
Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
The purpose of this study was to assess the effect of in-hospital initiation of sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following…
- Trial name
- PIONEER-HF (NCT02554890)
- Testing
- sacubitril/valsartan (LCZ696), Enalapril
- Where
- 123 sites in United States
- Volunteers
- 887 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II
Yoga Based Cardiac Rehabilitation in Heart Failure Failure
The clinical study compares the benefits of yoga based rehabilitation programme versus an educational package during recovery of patients with heart failure.
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- Yoga-CaRe HF (NCT07817589)
- Testing
- Yoga-CaRe HF, Health Education
- Where
- 16 sites in India
- Volunteers
- 3,500 people
- Sponsor
- Centre for Chronic Disease Control, India
Heart Failure With Reduced Ejection Fraction (HF-rEF)
Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)
Novartis has set up this global Multiple Patient Program (MPP) treatment plan to provide access to life-saving treatment with LCZ696 for patients that were not previously exposed to LCZ696 but have no other option to receive…
- Trial name
- NCT02389933
- Testing
- LCZ696
- Where
- 286 sites in United States, Australia and 16 more
- Sponsor
- Novartis Pharmaceuticals
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Whole Heart Radiotherapy for End-stage Heart Failure
End-stage heart failure (ESHF) causes recurrent hospitalizations, cardiac arrhythmias, and intolerance to standard HF therapies are common as the disease progresses.
- Conditions
- Heart Failure NYHA Class III, Heart Failure NYHA Class IV, End-stage Heart Failure, Heart Failure With Reduced Ejection Fraction
- Trial name
- ESHF-WHRT (NCT06299176)
- Testing
- Whole Heart Radiation Therapy
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Heart Failure, Heart Failure and Reduced Ejection Fraction
Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fraction With Limited Kidney Function Assessments
Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) constitutes of four medications that substantially reduce morbidity and mortality, and improve quality of life.
- Conditions
- Heart Failure, Heart Failure and Reduced Ejection Fraction, Heart Failure and Mildly Reduced Ejection Fraction
- Trial name
- RESUME-HF (NCT07275437)
- Testing
- Blinded kidney function assessments
- Where
- 2 sites in Netherlands
- Volunteers
- 344 people
- Sponsor
- University Medical Center Groningen
Heart Failure, Mortality
The Comparative Effectiveness Between ARNI and ACE Inhibitor/ARB Medication in Patient With HFrEF
This study aimed to evaluate the effectiveness, safety, and cost-effectiveness of ARNI and ACEi/ARBs in real-world practice. This study could find out what the unmet medical needs are in real world practice.
- Trial name
- PARADE-HF (NCT05329727)
- Testing
- Angiotensin receptor neprilysin inhibitor (ARNI), Renin-Angiotensin System Inhibitor (RAS inhibitor)
- Where
- South Korea
- Volunteers
- 1,000,000 people
- Sponsor
- Wonju Severance Christian Hospital
Heart Failure With Reduced Ejection Fraction
Ketones in Heart Failure With Reduced Ejection Fraction
The purpose of this study is to understand the effects of a ketone drink on exercise capacity and other cardiovascular parameters in patients with heart failure.
- Trial name
- HFrEF (NCT06195982)
- Testing
- ketone ester
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Duke University
Heart Failure, Heart Failure With Reduced Ejection Fraction
Thiamine Supplementation in Heart Failure: a Pilot Randomized Controlled Crossover Trial
Heart failure (HF) is a major cardiovascular disease with increasing prevalence. Thiamine deficiency is common in HF patients. Previous small studies have shown that thiamine supplementation can improve left ventricular systolic…
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Thiamine Deficiency, Congestive Heart Failure
- Trial name
- THIAMINE-HF (NCT03228030)
- Testing
- Thiamine
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Hamilton Health Sciences Corporation
Chronic Heart Failure, Left Ventricular (LV) Systolic Dysfunction
A Study Evaluating an Implantable Cardiac Microcurrent Device in Patients With Chronic Heart Failure
This study evaluates the safety and performance/effectiveness of the C-MIC System, an active implantable medical device designed to treat patients with heart failure with reduced ejection fraction (HFrEF).
- Conditions
- Chronic Heart Failure, Left Ventricular (LV) Systolic Dysfunction, Ischemic and Non-ischemic Cardiomyopathy
- Trial name
- NCT07795359
- Testing
- Subcutaneous cardiac microcurrent treatment
- Volunteers
- 60 people
- Sponsor
- Berlin Heals GmbH
Heart Failure (HF)
A Trial to Study BAY1753011 in Patients With Congestive Heart Failure
To assess the efficacy of 30 mg of BAY1753011, with or without furosemide, versus furosemide alone in patients with heart failure and objective evidence of congestion.
- Trial name
- AVANTI (NCT03901729)
- Testing
- BAY 1753011, Furosemide
- Where
- 66 sites in Austria, Bulgaria and 7 more
- Volunteers
- 482 people
- Sponsor
- Bayer
Heart Failure With Reduced Ejection Fraction, Chronic Heart Failure
Emulation of the EMPEROR-Reduced Trial Using Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07599345
- Testing
- Empagliflozin, Sitagliptin
- Where
- United States
- Volunteers
- 23,955 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure With Reduced Ejection Fraction, Hyperkalemia
Spanish Study of Hyperkalaemia Incidence and Prognosis in Patients With Heart Failure and Reduced Ejection Fraction
Participant centres and researchers: 20 National Public Health System hospitals. Cardiology specialist physicians Clinical Research Ethics Committee (CREC): Hospital 12 de Octubre, Madrid Main goal: To estimate prevalence and, in…
- Trial name
- SPANIK-HF (NCT04141800)
- Where
- Spain
- Volunteers
- 565 people
- Sponsor
- Spanish Society of Cardiology